Page 69 - 南京医科大学自然版

第44卷第7期 魏艳秋，季辰菲，孙 伟，等. 肺癌合并免疫检查点抑制剂相关肺炎的临床特征和预后分析［J］.
2024年7月 南京医科大学学报（自然科学版），2024，44（7）：947-953 ·953 ·

［16］TEOH A K Y，CORTE T J. Nonspecific interstitial pneu⁃ point inhibitor⁃related pneumonitis in lung cancer patients：
monia［J］. Semin Respir Crit Care Med，2020，41（2）： a multicenter experience［J］. Transl Lung Cancer Res，

184-201 2021，10（1）：415-429
［17］SURESH K，PSOTER K J，VOONG K R，et al. Impact of ［26］LARSEN B T，CHAE J M，DIXIT A S，et al. Clinical and
checkpoint inhibitor pneumonitis on survival in NSCLC histopathologic features of immune checkpoint inhibitor⁃
patients receiving immune checkpoint immunotherapy［J］. related pneumonitis［J］. Am J Surg Pathol，2019，43（10）：
J Thorac Oncol，2019，14（3）：494-502 1331-1340
［18］TONE M，IZUMO T，AWANO N，et al. High mortality and ［27］NAKANISHI Y，MASUDA T，YAMAGUCHI K，et al. Pre⁃
poor treatment efficacy of immune checkpoint inhibitors existing interstitial lung abnormalities are risk factors for
in patients with severe grade checkpoint inhibitor pneu⁃ immune checkpoint inhibitor ⁃ induced interstitial lung
monitis in non⁃small cell lung cancer［J］. Thorac Cancer， disease in non⁃small cell lung cancer［J］. Respir Investig，
2019，10（10）：2006-2012 2019，57（5）：451-459
［19］ MOEY M Y Y，GOUGIS P，GOLDSCHMIDT V，et al. ［28］RAGHU G，REMY⁃JARDIN M，RICHELDI L，et al. Idio⁃
Increased reporting of fatal pneumonitis associated with pathic pulmonary fibrosis（an update）and progressive
immune checkpoint inhibitors：a WHO pharmacovigi⁃ pulmonary fibrosis in adults：an official ATS/ERS/JRS/
lance database analysis［J］. Eur Respir J，2020，55（6）： ALAT clinical practice guideline［J］. Am J Respir Crit
2000038 Care Med，2022，205（9）：e18-e47
［20］GOMATOU G，TZILAS V，KOTTEAS E，et al. Immune ［29］TAKAHARA Y，TANAKA T，ISHIGE Y，et al. Risk fac⁃
checkpoint inhibitor⁃related pneumonitis［J］. Respiration， tors for acute exacerbation in lung cancer complicated by
2020，99（11）：932-942 interstitial lung disease with slight reticular shadows［J］.
［21］YIN J，WU Y，YANG X，et al. Checkpoint inhibitor pneu⁃ Thorac Cancer，2021，12（20）：2758-2766
monitis induced by anti⁃PD⁃1/PD⁃L1 therapy in non⁃small⁃ ［30］ZHANG Q，TANG L，ZHOU Y，et al. Immune checkpoint
cell lung cancer：occurrence and mechanism［J］. Front inhibitor ⁃ associated pneumonitis in non ⁃ small cell lung
Immunol，2022，13：830631 cancer：current understanding in characteristics，diagno⁃
［22］POSTOW M A，SIDLOW R，HELLMANN M D. Immune⁃ sis，and management［J］. Front Immunol，2021，12：
related adverse events associated with immune check⁃ 663986
point blockade［J］. N Engl J Med，2018，378（2）：158-168 ［31］NISHINO M，RAMAIYA N H，AWAD M M，et al. PD⁃1
［23］ KIM S，LIM J U. Immune checkpoint inhibitor⁃related inhibitor⁃related pneumonitis in advanced cancer patients：
interstitial lung disease in patients with advanced non ⁃ radiographic patterns and clinical course［J］. Clin Cancer
small cell lung cancer：systematic review of characteris⁃ Res，2016，22（24）：6051-6060
tics，incidence，risk factors，and management［J］. J Thorac ［32］IMRAN S，GOLDEN A，FEINSTEIN M，et al. Immune
Dis，2022，14（5）：1684-1695 check ⁃ point inhibitor ⁃ related pneumonitis：acute lung
［24］ALLEN E，UMORU G，AJEWOLE V，et al. Incidence and injury with rapid progression and organising pneumonia
outcome of immune checkpoint ⁃ induced pneumonitis in with less severe clinical disease［J］. Histopathology，
oncology patients with history of pulmonary disease［J］. 2022，81（6）：724-731
Front Oncol，2023，13：1283360 ［收稿日期］ 2024-01-23
［25］LIN X，DENG H，CHEN L，et al. Clinical types of check⁃ （本文编辑：唐 震）